Literature DB >> 31700814

Burden of Clostridium (Clostridioides) difficile Infection among Patients in Western Asia: A Systematic Review and Meta-Analysis.

Yalda Malekzadegan1, Mehrdad Halaji2,3, Meysam Hasannejad-Bibalan4, Saba Jalalifar2, Javad Fathi1, Hadi Sedigh Ebrahim-Saraie5.   

Abstract

BACKGROUND: Clostridium difficile is the most common causes of hospital-acquired diarrhea affecting particularly hospitalized patients globally. This organism has re-emerged in recent years with significant morbidity and mortality. The present study aimed to estimate the burden of C. difficile infection (CDI) and to acquire information on the overall rates of community- and hospital-acquired CDI in western Asia.
METHODS: A systematic literature search was performed to identify articles published from the eight Persian Gulf countries in western Asia including Iran, Iraq, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates in the electronic databases within Jan of 2000 to Dec of 2017. Then, 20 publications which met our inclusion criteria were selected for data extraction and analysis by Comprehensive Meta-Analysis Software.
RESULTS: Twenty studies reported the prevalence of toxigenic strains of C. difficile among patients from Persian Gulf countries, of these the pooled prevalence of CDI was 9% (95% CI: 6.5%-12.5%). Totally, 8 studies showed the prevalence of hospital-acquired CDI, from those studies the prevalence of CDI was estimated 8.4% (95% CI: 4.9%-14.1%). Moreover, 7 studies reported the prevalence of community-acquired CDI, from those studies the prevalence of CDI was estimated 1.8% (95% CI: 1.2%-2.9%).
CONCLUSION: The prevalence of CDI in western Asia is lower than southern and eastern region. Moreover, the lower prevalence of community-acquired CDI compared to hospital-acquired CDI, indicate that the source of infection in western Asia is more likely in the hospitals. Copyright© Iranian Public Health Association & Tehran University of Medical Sciences.

Entities:  

Keywords:  Clostridium difficile infection (CDI); Infection control; Meta-analysis; Western Asia

Year:  2019        PMID: 31700814      PMCID: PMC6825664     

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.429


Introduction

Hospital-acquired infections (HAIs) are a serious public health concern resulting in prolonged hospitalization and risk of death (1). The occurrence of HAIs according to the WHO estimates is around 7.1 million cases every year (2). Among the wide range of bacteria has been reported as a cause of HAIs, vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae are the most prevalent pathogens (3, 4). Clostridium difficile is the most common cause of hospital-acquired diarrhea affecting particularly hospitalized patients globally (5). This organism has re-emerged in recent years with apparent greater morbidity and mortality and also associated with increased health care costs (6). Factors contributing to the development of this phenomenon include usage of broad-spectrum antibiotics such as fluoroquinolones, clindamycin and third generation cephalosporin’s as well as prolonged hospitalization, antineoplastic chemotherapy, and severe underlying diseases (7, 8). Treatment of C. difficile infection (CDI) is challenging and demand new approaches because most of antibiotics used for the treatment of every kind of infections can potentially encourage CDI (9, 10). The currently available antibiotics that remain the first-line therapy for CDI are metronidazole and vancomycin (11, 12). Antibiotic-associated diarrhea is mostly linked to strains of C. difficile that produce a range of virulence factors including toxins and adherence factors (13). Toxin A (TcdA) and toxin B (TcdB) are two homologous exotoxin and main virulence factors of toxigenic C. difficile that encoded by the tcdA and tcdB genes, respectively. Expression of these toxins causing proinflammatory and cytotoxic effects including disruption of the actin cytoskeleton and impairment of tight junctions in human intestinal epithelial cells that are responsible for the clinical symptoms of CDI (13). The incidence of CDIs is an important quality indicator to reflect the effectiveness of the basic hospital policies include infection control and antimicrobial stewardship. The objectives of the present study were to estimate the burden of CDI and to acquire information on the overall rates of community- and hospital-acquired CDI in western Asia. Results from this survey indicate progress across Persian Gulf countries towards comprehensive monitoring and reporting of CDI.

Methods

Search strategies

A systematic literature search was performed to identify papers published from the eight Persian Gulf countries in western Asia including Iran, Iraq, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates in the Web of Science, PubMed, Scopus, and Google Scholar electronic databases within Jan of 2000 to Dec of 2017. The keywords and terms were searched using Medical Subject Headings (MeSH) such as “Clostridium difficile” or “Clostridioides difficile” or “C. difficile” or “Clostridium difficile infection (CDI)” or “Pseudomembranous colitis” in combination with “Names of countries” in the title, abstract and keywords fields.

Selection criteria

Two reviewers independently screened the search results at the databases with the related keywords and analysis the titles, abstracts, and full texts to applied eligibility for inclusion according to inclusion criteria, and the disagreement between reviewers was resolved by consensus. English and Persian or Arabian language articles with English abstract indexed in PubMed, Scopus or Web of Science with the following criteria were considered in our study: 1) Clearly mentioned to method used for C. difficile and toxins detection; 2) cross-sectional or retrospective studies investigating the prevalence of toxigenic C. difficile collected from diarrhea samples. Meanwhile, exclusion criteria were: 1) studies that did not report a standardized method for detection of C. difficile and toxins; 2) studies with sample size was less than 10 isolates; 3) studies that origin of samples was unclear or isolates obtained from formed stool or environment sources, and 4) studies which focused on non-toxigenic C. difficile or the prevalence of toxigenic strains was unclear. Furthermore, reviews and systematic review articles, case reports, and articles which were only available in abstract form were ignored.

Definition

According to the European Center for Disease Prevention and Control (ECDC), an episode of CDI was defined as a patient with diarrhea whose stool takes the shape of the container, and it is positive for C. difficile toxin A and/ or B without other etiology (14).

Quality assessment

The quality of eligible studies was judged independently by two authors using the STROBE checklist (Strengthening the Reporting of Observational Studies in Epidemiology). Items related title and abstract, introduction, methods, results, discussion, and other information were determined and a score was assigned to each item. One score was assigned to each question and studies achieved at least eight quality scores were considered eligible and included in the study (15).

Data extraction

For all selected studies, the following details were extracted: the first author’s name, the study performing time, publication date, research location, sample type, patients age range, nature of patients (hospitalized or outpatient), toxins detection methods, primary sample size, the frequency of toxigenic C. difficile, source of infection, origin of infection, and proportion of toxigenic strains in each gender.

Statistical analysis

Analysis of data was performed using Comprehensive Meta-Analysis Software Ver. 2.2 (BioStat Company). Meta-analysis was performed using random-effects model to estimate the pooled prevalence and corresponding 95% confidence interval (CI). Statistical heterogeneity between and within groups was determined using Cochran’s Q statistic and the I2 index. The funnel plot, Begg’s rank correlation test, and Egger’s weighted regression tests were used to evaluate possible publication bias (P<0.05 is indicative of publication bias). The present study designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results

Initially, 5440 citations were yielded from the database search. Among them, 5404 were excluded on the initial screening of the index, title and abstract and 36 were reviewed in full text. Of 36 full text reviewed articles, five studies did not report the prevalence of toxigenic strains of C. difficile, four studies did not report primary samples size, three studies had unclear results, three studies performed on random stools, and results of one study duplicated in their recent study. Finally, 20 studies were eligible for inclusion and were subjected to meta-analysis. A flowchart of the literature search, the selection procedures and reasons for exclusion are presented in Fig. 1. The characteristics of the included studies in the meta-analysis are available in Table 1.
Fig. 1:

Flow chart of the literature search strategy and study selection

Table 1:

Characteristics of studies included in the meta-analysis

First authorPublication yearPreformed timeCountrySample typeAge rangeHospitalized (H) or outpatient (OP)Detection methodSample sizeToxigenic C. difficile No.HA/CA No.M/F No.Ref
Sadeghifard20102002–2006IranDiarrheal stoolNo limitHCytotoxicity assay94257-30/27(16)
Nazemalhosseini-Mojarad2011UNIranDiarrheal stoolNo limitH and OPELISA35619-13/6(17)
Nasri20122009–2010IranDiarrheal stoolNo limitHELISA16236-24/12(18)
Jalali20122010–2011IranDiarrheal stoolNo limitHMolecular861713/49/8(19)
Goudarzi20132010–2011IranDiarrheal stoolNo limitHMolecular35075-39/36(20)
Farshad20132012IranNosocomial diarrheaNo limitHCytotoxicity assay and ELISA12299/-5/4(21)
Azizi20132010IranNosocomial diarrheaNo limitHMolecular9815--(22)
Alinejad20152013–2014IranNosocomial diarrhea6–60 monthsHELISA3888/-6/2(23)
Rezazadeh Zarandi20172014–2015IranDiarrheal stoolNo limitHMolecular and ELISA23311--(24)
Azimirad20172011–2012IranDiarrheal stoolNo limitHMolecular10518-9/10(25)
Sandokji20092007–2008Saudi ArabiaDiarrheal stool>2 yrHELISA2585656/--(26)
Al-Tawfiq20102007–2008Saudi ArabiaDiarrheal stoolNo limitH and OPELISA9134226/1623/19(27)
AL-Eidan20132011Saudi ArabiaDiarrheal stoolAdultHELISA292717198/73-(28)
Senok20172014–2015Saudi ArabiaDiarrheal stoolNo limitH and OPMolecular21031--(29)
Jamal20102003–2005KuwaitDiarrheal stoolNo limitH and OPELISA6977356/17-(30)
Jamal20142012KuwaitDiarrheal stool>2 yrOPMolecular40913-/13-(31)
Jamal20152011–2013KuwaitDiarrheal stool>2 yrOPELISA254816-/16-(32)
Albert20162014–2015KuwaitDiarrheal stoolNo limitHMolecular1093--(33)
Alrifai20092004–2005IraqNosocomial diarrhea1–60 monthsHELISA8117-(34)
Al-Thani20142011–2012QatarDiarrheal stool>1 yrH and OPEIA and Molecular1,53212298/1472/50(35)

Abbreviations: ELISA: enzyme-linked immunosorbent assay; EIA: Enzyme Immunoassay; HA: hospital-acquired; CA: community-acquired; M: male; F: female.

Flow chart of the literature search strategy and study selection Characteristics of studies included in the meta-analysis Abbreviations: ELISA: enzyme-linked immunosorbent assay; EIA: Enzyme Immunoassay; HA: hospital-acquired; CA: community-acquired; M: male; F: female. Of the total number of included studies, 10 of which were from Iran (16–25), four from Saudi Arabia (26–29), four from Kuwait (30–33), and one for each of Iraq (34), and Qatar countries (35). Totally, 13 studies conducted only among hospitalized patients, five studies contained both hospitalized and outpatients and two studies enrolled only outpatients. Twenty studies reported the prevalence of toxigenic strains of C. difficile among patients from Persian Gulf countries, of these the pooled prevalence of CDI was 9% (95% CI: 6.5%–12.5%) ranging from 0.6% to 22.2% (Fig. 2). There was a significant heterogeneity among the included studies (χ2 = 410.893; P<0.001; I2 =95.4%). Moreover, a symmetric funnel plot of the included studies showed no evidence of publication bias (Fig. 3). Additionally, Begg’s and Egger’s tests were performed to quantitatively evaluate the probable publication bias among studies. According to the results of Begg’s test (z=0.097, P=0.92) and Egger’s test (t=0.34, P=0.74), no evidence of publication bias was observed.
Fig. 2:

Forest plot of the pooled prevalence of CDI in western Asia

Fig. 3:

Funnel plot of meta-analysis on CDI in western Asia

Forest plot of the pooled prevalence of CDI in western Asia Funnel plot of meta-analysis on CDI in western Asia Totally, eight studies showed the prevalence of hospital-acquired CDI, from those studies the prevalence of CDI was estimated 8.4% (95% CI: 4.9%–14.1%) ranging from 2.8% to 21.7% (Fig. 4).
Fig. 4:

Forest plot of the pooled prevalence of community- or hospital-acquired

Forest plot of the pooled prevalence of community- or hospital-acquired Moreover, seven studies reported the prevalence of community-acquired CDI, from those studies the prevalence of CDI was estimated 1.8% (95% CI: 1.2%–2.9%) ranging from 0.6% to 4.7% (Fig. 4). Ten studies showed the incidence of CDI regarding gender, from those studies the occurrence of CDI among male and female patients was estimated 6% (95% CI: 4%–9%) and 4.6% (95% CI: 3.0%–7.1%), respectively (Fig. 5). Finally, subgroups analysis between countries were done and results were presented in Fig. 6.
Fig. 5:

Forest plot of the pooled prevalence of male and female patients with CDI

Fig. 6:

Forest plot of subgroups analysis of the pooled prevalence of CDI between countries in western Asia

Forest plot of the pooled prevalence of male and female patients with CDI Forest plot of subgroups analysis of the pooled prevalence of CDI between countries in western Asia

Discussion

The emergence of the hypervirulent C. difficile strains increase the prevalence and severity of CDI; however, epidemic strain of NAP1/BI/027 is not common in our region and is a public health problem for other countries, mainly western countries (36). Thus, it is essential to gain a close estimation of the burden of CDI for the development of effective healthcare practice. To the best of our knowledge, the present study is the largest comprehensive survey to date estimated the pooled prevalence of CDI 9% from the Persian Gulf region. Moreover, the prevalence of CDI differed greatly between studied countries and even hospitals in the same country ranging from 0.6% to 22.2%. Despite the discrepancy in literature, our findings are consistent with the median values reported in previous studies. In this regard, the prevalence of CDI in South and East Asia were reported 10.9% in India (37), 14% in China (38), and 14.3% in South-Korea (39). These reports, accompanied by results from a meta-analysis study that indicated the prevalence of CDI in Eastern Asia is higher than other parts (40). In American countries, this rate was reported 8% in Brazil (41), and 13.7% in the USA (42). While a hospital-based survey within 34 European countries showed much more discrepancy in the prevalence of CDI ranging from 0% in Luxembourg to 39% in Poland (43). These variations might be due to differences in predominant epidemic strains, geographical distribution, studied population or the sensitivity of detection methods. In the present study, from those studies that reported the origin of infection, the prevalence of hospital-acquired CDI was estimated at 8.4%, while the prevalence of community-acquired CDI was 1.8%. International estimation of the burden of community- or hospital-acquired CDI is challenging since in most of the studies the origin of infection was not investigated. Comparison with available reports indicate that the prevalence of community-acquired CDI in our study (1.8%) is closest to reports from Brazil (1%) (41), South-Korea (1.6%) (39), and Europe (∼2%) (43), whereas it is lower than report from China (8%) (44). The strengths of this systematic review based study were the large number of patients from the major countries of Middle East with a study design adherence to international guidelines for the estimating burden of CDI. Based on the ECDC experiences, continuous or periodical surveillance supplemented with epidemiological and microbiological data is a practical strategy for monitoring CDI (45). Meanwhile, increasing the national coverage of hospital-based CDI surveillance will improve the national estimates of the CDI burden (43, 45). As the main limitation of the present study, our report was not representative of the actual rate in the Persian Gulf region. Since our estimation was based on published data, so the burden of infection would be expected to be different if a network of data from more hospitals and laboratories in this region were available. Moreover, differences in the severity of illness of patients or antibiotics prescription might be an effect on reporting rates (43).

Conclusion

The results of the present study provide good epidemiological information about the distribution of CDI in the Persian Gulf region in western Asia. The prevalence of CDI in western Asia is lower than southern and eastern region. Moreover, the lower prevalence of community-acquired CDI compared to hospital-acquired CDI, indicate that the source of infection in western Asia is more likely in the hospitals. These findings highlighting the importance of active surveillance, and the demand for improving infection control policy in reducing the risk of CDI in hospitals.

Ethical consideration

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.
  40 in total

1.  Clostridium difficile-associated disease among patients in Dhahran, Saudi Arabia.

Authors:  Jaffar A Al-Tawfiq; Mahmoud S Abed
Journal:  Travel Med Infect Dis       Date:  2010-10-27       Impact factor: 6.211

Review 2.  Epidemiology of multidrug-resistant Acinetobacter baumannii strains in Iran: a systematic review and meta-analysis.

Authors:  Abed Zahedi Bialvaei; Ebrahim Kouhsari; Amin Salehi-Abargouei; Nour Amirmozafari; Rashid Ramazanzadeh; Ali Ghadimi-Daresajini; Mansour Sedighi
Journal:  J Chemother       Date:  2017-06-16       Impact factor: 1.714

3.  Standardised surveillance of Clostridium difficile infection in European acute care hospitals: a pilot study, 2013.

Authors:  Sofie M van Dorp; Pete Kinross; Petra Gastmeier; Michael Behnke; Axel Kola; Michel Delmée; Anastasia Pavelkovich; Silja Mentula; Frédéric Barbut; Agnes Hajdu; André Ingebretsen; Hanna Pituch; Ioana S Macovei; Milica Jovanović; Camilla Wiuff; Daniela Schmid; Katharina Ep Olsen; Mark H Wilcox; Carl Suetens; Ed J Kuijper
Journal:  Euro Surveill       Date:  2016-07-21

4.  Comparative performance of the GeneXpert C. difficile PCR assay and C. diff Quik Chek Complete kit assay for detection of Clostridium difficile antigen and toxins in symptomatic community-onset infections.

Authors:  Wafaa Jamal; Eunice M Pauline; Vincent O Rotimi
Journal:  Int J Infect Dis       Date:  2014-11-13       Impact factor: 3.623

5.  Risk factors for Clostridium difficile infection.

Authors:  G E Bignardi
Journal:  J Hosp Infect       Date:  1998-09       Impact factor: 3.926

6.  Prevalence and molecular types of Clostridium difficile isolates from faecal specimens of patients in a tertiary care centre.

Authors:  Chetana Vaishnavi; Meenakshi Singh; Safrun Mahmood; Rakesh Kochhar
Journal:  J Med Microbiol       Date:  2015-09-10       Impact factor: 2.472

7.  Healthcare - associated infections: A public health problem.

Authors:  Angela Revelas
Journal:  Niger Med J       Date:  2012-04

8.  Clostridium difficile infection in an Iranian hospital.

Authors:  Mohammad Jalali; Farzin Khorvash; Keith Warriner; J Scott Weese
Journal:  BMC Res Notes       Date:  2012-03-21

9.  Emergence of an outbreak-associated Clostridium difficile variant with increased virulence.

Authors:  Carlos Quesada-Gómez; Diana López-Ureña; Luis Acuña-Amador; Manuel Villalobos-Zúñiga; Tim Du; Rosemayre Freire; Caterina Guzmán-Verri; María del Mar Gamboa-Coronado; Trevor D Lawley; Edgardo Moreno; Michael R Mulvey; Gerly Anne de Castro Brito; Evelyn Rodríguez-Cavallini; César Rodríguez; Esteban Chaves-Olarte
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

Review 10.  Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects.

Authors:  Stefano Di Bella; Paolo Ascenzi; Steven Siarakas; Nicola Petrosillo; Alessandra di Masi
Journal:  Toxins (Basel)       Date:  2016-05-03       Impact factor: 4.546

View more
  3 in total

1.  Characteristics of patients infected with Clostridioides difficile at a Saudi Tertiary Academic Medical Center and assessment of antibiotic duration.

Authors:  Khadijah M Alammari; Abrar K Thabit
Journal:  Gut Pathog       Date:  2021-02-17       Impact factor: 4.181

2.  Frequency of toxin genes and antibiotic resistance pattern of Clostridioides difficile isolates in diarrheal samples among hospitalized patients in Hamadan, Iran.

Authors:  Leili Shokoohizadeh; Fatemeh Alvandi; Abbas Yadegar; Masoumeh Azimirad; Seyed Hamid Hashemi; Mohammad Yousef Alikhani
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021

3.  Prevalence and antimicrobial resistance pattern of Clostridium difficile among hospitalized diarrheal patients: A systematic review and meta-analysis.

Authors:  Tebelay Dilnessa; Alem Getaneh; Workagegnehu Hailu; Feleke Moges; Baye Gelaw
Journal:  PLoS One       Date:  2022-01-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.